title: Pyruvate in oral rehydration salt improves hemodynamics, vasopermeability and survival after burns in dogs.
abstract: BACKGROUND
  To investigate whether pyruvate-enriched oral rehydration solution (Pyr-ORS), compared with citrate-enriched ORS (Cit-ORS), improves hemodynamics and organ function by alleviating vasopermeability and plasma volume loss during intra-gastric fluid rehydration in dogs with severe burn.
  
  
  METHODS
  Forty dogs subjected to severe burn were randomly divided into four groups (n=10): two oral rehydrated groups with Pyr-ORS and Cit-ORS (group PR and group CR), respectively, according to the Parkland formula during the first 24h after burns. Other two groups were the intravenous (IV) resuscitation (group VR) with lactated Ringer's solution with the same dosage and no fluid rehydration (group NR). During the next 24h, all groups received the same IV infusion. The hemodynamics, plasma volume, vasopermeability and water contents and function of various organs were determined. Plasma levels of vascular endothelial growth factor (VEGF) and platelet activating factor (PAF) were detected by ELISA.
  
  
  RESULTS
  Hemodynamics parameters were significantly improved in group PR superior to group CR after burns. Levels of VEGF and PAF were significantly lower in group PR than in group CR. Organ function parameters were also greatly preserved in group PR, relative to groups CR and NR. Lactic acidosis was fully corrected and survival increased in group PR (50.0%), compared to group CR (20.0%).
  
  
  CONCLUSIONS
  Pyr-ORS was more effective than Cit-ORS in improving hemodynamics, visceral blood perfusion and organ function by alleviating vasopermeability-induced visceral edema and plasma volume loss in dogs with severe burn.
authors.affiliation: Department of Burns, the Fifth Hospital of Harbin, Harbin, 150040, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Liu
authors.affiliation: Laboratory for Shock and Multiple Organ Dysfunction of Burns Institute, Key Research Laboratory of Tissue Repair and Regeneration of PLA, and Beijing Key Research Laboratory of Skin Injury and Repair Regeneration, First Hospital Affiliated to the Chinese PLA General Hospital, Beijing 100048, China; School of Medical Science, Faculty of Science Office, Level 2, Carslaw Building (F07), University of Sydney, NSW 2006, Australia.
authors.forename: Xiao-Hang
authors.initials: XH
authors.lastname: Hu
authors.affiliation: Department of Emergency Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
authors.forename: Shu-Ming
authors.initials: SM
authors.lastname: Wang
authors.affiliation: Department of Human Resources, the First Hospital of Harbin, Harbin 150010, China.
authors.forename: Si-Jia
authors.initials: SJ
authors.lastname: Guo
authors.affiliation: Department of Burns, the Fifth Hospital of Harbin, Harbin, 150040, China.
authors.forename: Zong-Yu
authors.initials: ZY
authors.lastname: Li
authors.affiliation: Department of Burn Surgery, the General Hospital of Armed Police Forces, Beijing 100039, China. Electronic address: 2237978564@qq.com.
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Bai
authors.affiliation: Shanghai Sandai Pharmaceutical R&D Co., Pudong, Shanghai 201203, China. Electronic address: fqzh60130@yahoo.com.
authors.forename: Fang-Qiang
authors.initials: FQ
authors.lastname: Zhou
authors.affiliation: Laboratory for Shock and Multiple Organ Dysfunction of Burns Institute, Key Research Laboratory of Tissue Repair and Regeneration of PLA, and Beijing Key Research Laboratory of Skin Injury and Repair Regeneration, First Hospital Affiliated to the Chinese PLA General Hospital, Beijing 100048, China. Electronic address: bs0425@163.com.
authors.forename: Sen
authors.initials: S
authors.lastname: Hu
mesh_terms: D000818:Animals; D001639:Bicarbonates; D002056:Burns / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D002199:Capillary Permeability / Q000187:drug effects*; D004195:Disease Models, Animal; D004285:Dogs; D005440:Fluid Therapy / Q000379:methods*; D016650:Fluorescein-5-isothiocyanate / Q000032:analysis; D005947:Glucose; D006439:Hemodynamics / Q000187:drug effects*; D019344:Lactic Acid / Q000378:metabolism; D010972:Platelet Activating Factor / Q000378:metabolism; D011189:Potassium Chloride; D019289:Pyruvic Acid / Q000494:pharmacology*; D011897:Random Allocation; D012769:Shock / Q000188:drug therapy; D012965:Sodium Chloride; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D001639:Bicarbonates; D010972:Platelet Activating Factor; D042461:Vascular Endothelial Growth Factor A; C044142:World Health Organization oral rehydration solution; D019344:Lactic Acid; D012965:Sodium Chloride; D011189:Potassium Chloride; D019289:Pyruvic Acid; D016650:Fluorescein-5-isothiocyanate; D005947:Glucose
keywords: Burn; Oral rehydration salt; Organ function; Pyruvate; Shock; Vasopermeability